Tesamorelin vs CJC-1295: GHRH Analog Research Comparison
Compare tesamorelin (FDA-approved GHRH analog) and CJC-1295 — pharmacokinetics, pulsatility, IGF-1 response, and published research findings.
Tesamorelin and CJC-1295 are both stabilised GHRH analogs, but they were developed for different research goals: tesamorelin for clinically validated visceral-adipose reduction; CJC-1295 for pulsatile or sustained GH-axis research depending on DAC variant. This comparison summarises the published literature relevant to laboratory research.
At-a-glance comparison
| Attribute | Tesamorelin | CJC-1295 | |---|---|---| | Class | GHRH analog (trans-3-hexenoyl-GRF(1-44)) | GHRH analog (tetra-substituted GRF(1-29)) | | Stabilisation strategy | N-terminal acyl group resists DPP-IV | Tetra-substitution + optional DAC albumin tether | | Half-life | ~26-38 minutes (subcutaneous) | ~30 min (no-DAC) or ~8 days (DAC) | | Pulsatility | Preserved | Preserved (no-DAC); tonic (DAC) | | Regulatory status | FDA-approved (Egrifta) for HIV lipodystrophy | Research only | | Most-cited research endpoint | Visceral adipose tissue reduction | IGF-1 elevation, GH pulse amplitude |
Mechanism
Both bind the pituitary GHRH receptor on somatotrophs and trigger endogenous pulsatile GH release. Both preserve negative-feedback regulation by somatostatin and IGF-1 — distinguishing them from exogenous GH administration. The structural difference is the stabilisation strategy: tesamorelin uses an N-terminal acyl modification; CJC-1295 uses backbone substitution plus optional DAC albumin binding.
Pharmacokinetics — the central distinction
Tesamorelin's half-life sits between sermorelin (~10-20 min) and CJC-1295 no-DAC (~30 min) — close enough to native GHRH to preserve pulsatility. CJC-1295 DAC's ~8-day half-life produces tonic GHRH-receptor exposure, a fundamentally different signalling pattern that elevates basal IGF-1 across the dosing interval.
Published research highlights
- Tesamorelin's Phase 3 trials in HIV-associated lipodystrophy demonstrated significant visceral adipose tissue reduction (~15-18%) at 26 weeks, leading to FDA approval as Egrifta.
- CJC-1295 (no-DAC) is most-cited in combination research with ghrelin-receptor agonists (ipamorelin, GHRP-2) for additive GH pulse amplitude.
- CJC-1295 DAC research is most-cited for sustained IGF-1 elevation from weekly dosing.
Selecting between them in research
- For published clinical-translation context: tesamorelin (FDA precedent for VAT reduction).
- For pulsatile GH-axis research: tesamorelin or CJC-1295 no-DAC.
- For sustained tonic IGF-1 elevation with weekly dosing: CJC-1295 DAC.
Frequently asked research questions
Why has tesamorelin advanced clinically while CJC-1295 hasn't? Tesamorelin had a specific clinical indication (HIV-lipodystrophy VAT) with measurable endpoints. CJC-1295's broader research positioning never crystallised into a single Phase 3 indication.
Do they share the same safety signature? Both classes share the GHRH-class profile: injection-site reactions, transient glucose elevation, fluid retention at higher doses. Tesamorelin has the larger controlled-trial safety dataset.
Related research
- HGH vs Tesamorelin research comparison
- CJC-1295 vs Ipamorelin research comparison
- CJC-1295 vs Sermorelin research comparison
Related Research Articles
What is BPC-157? A Research Primer
A comprehensive research primer on BPC-157 (Body Protection Compound-157) — a pentadecapeptide derived from human gastric juice. Covers origins, mechanism of action, tendon and gut healing research, angiogenesis, and CNS research findings.
Peptide Reconstitution 101
A complete step-by-step guide to reconstituting lyophilized research peptides. Covers bacteriostatic water vs sterile water, reconstitution math, injection technique, storage after reconstitution, and common mistakes to avoid.
GHK-Cu Research Overview
A copper-binding tripeptide endogenous to human plasma, studied extensively in wound healing, collagen synthesis, antioxidant defense, and gene expression regulation within cellular research models.